Insights

What’s happening with the Rhythm (ASX:RHY) share price today?

The Rhythm Biosciences Ltd (ASX: RHY) share price is sinking today, despite announcing a positive update to its ColoSTAT trial program.
The post What’s happening with the Rhythm (ASX:RHY) share price today? appeared first on The Motley Fool Australia. –

women with virtual question marks above her head "thinking"

The Rhythm Biosciences Ltd (ASX: RHY) share price is sinking today, despite announcing an additional site to its ColoSTAT clinical trial program.

During the first hour of open, shares in the medical device company fell to an intraday low of $1.435. However, some bargain hunter swopped in on the opportunity, rebounding the price to $1.44, down 7.4% in afternoon trade.

What did Rhythm announce?

The Rhythm share price is on the move in the opposite direction after announcing a positive update.

According to its release, Rhythm advised that the Sunshine Coast University Hospital in Queensland will participate in the ColoSTAT trial. This will be the tenth site that is now aiming to study the safety and effectiveness of the prototype test kits.

Rhythm’s ColoSTAT is an experimental test-kit that is being trialled as a low-cost, easy-to-use blood test to detect colorectal cancer.

Located just 9 kilometres north from Caloundra, the hospital has become the first site to undertake ColoSTAT trials within the state. The hospital provides an array of public health services across Sunshine Coast, Gympie, and Noosa communities. Furthermore, the building houses a dedicated centre for clinical research programs including gastroenterology nurses as study coordinators to facilitate recruitment.

The company appointed principal investigator, Dr. Andrew Sloss, to oversee the ColoSTAT clinical trials. Dr. Sloss is a respected Gastroenterologist and Senior Lecturer at the University of Queensland.

Management commentary

Principal investigator, Dr. Andrew Sloss, commented on the prospects of advancing ColoSTAT. He said:

We currently treat hundreds of bowel cancer patients each year, which highlights the significant public need for effective screening and early intervention. ColoSTAT presents us with this opportunity to do both, ultimately easing the burden on the health system, and more importantly, to save lives.

Rhythm CEO, Mr. Glenn Gilbert added:

A milestone of ten sites now participating in our ColoSTAT clinical trial ensures we remain on track to positively impact people’s lives, by delivering a simple way to detect colorectal cancer early. Whilst an Australian invention, beginning at the CSIRO, Rhythm’s aim is to address the global market through mass screening programs.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,500%. The company’s shares were trading at 4.1 cents in March before accelerating later that year.

It is worth noting that the Rhythm share price is trading just below its all-time high of $1.60, reached yesterday.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What’s happening with the Rhythm (ASX:RHY) share price today? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!